Integrin α10high MSC Isolation for Cartilage Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cartilage damage and osteoarthritis are inadequate, as they only alleviate symptoms without preventing disease progression or worsening, and there is a need for effective prevention and treatment methods for subchondral bone sclerosis and degenerative joint diseases.
Innovation Solution
The use of an enriched population of mesenchymal stem cells (MSCs) expressing high levels of integrin α10, isolated and cultured to induce and expand their chondrogenic differentiation potential, which are administered to treat and prevent subchondral bone sclerosis, traumatic joint injuries, and degenerative disc disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MSC preparations are used for cartilage repair, then cell transplantation can be performed, but the cells are heterogeneous and poorly defined, leading to variable therapeutic efficacy
Solution Approach 1:
The patent extracts and isolates a specific subset of mesenchymal stem cells expressing integrin α10 from the heterogeneous MSC population. This selective extraction of cells with the desired phenotype (integrin α10high) ensures a well-defined, homogeneous cell population with consistent chondrogenic differentiation potential, thereby improving both manufacturing precision and therapeutic reliability
Solution Approach 2:
The patent applies local quality by selecting cells with a specific marker expression profile (integrin α10high) rather than treating all MSCs uniformly. This targeted selection ensures that only cells with the desired chondrogenic potential are used for therapy, creating a localized quality standard within the cell population that enhances treatment consistency and efficacy
2Object-generated harmful factors
If current treatment methods are used for cartilage damage, then symptom relief can be achieved, but disease progression is not prevented and cartilage continues to degrade
Solution Approach 1:
The patent employs preliminary action by administering integrin α10high MSCs prophylactically to prevent cartilage degradation before it occurs or progresses. The cells are introduced early to establish a protective effect, modifying the disease course before significant damage accumulates, thereby preventing rather than just treating symptoms
Solution Approach 2:
The patent converts the harmful inflammatory response and cartilage degradation process into a beneficial opportunity for regeneration. By introducing MSCs that can differentiate into chondrocytes and produce extracellular matrix, the therapy transforms the degenerative environment into one that promotes repair and prevents further damage
Data Source
AI summary
Compositions and methods for the prevention and/or treatment of conditions involving disease or damage in mammalian cartilage and bone, using mesenchymal stem cells isolated with anti-integrin α10 antibodies are disclosed.